Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK …
Mutant-selective KRASG12C inhibitors, such as MRTX849 (adagrasib) and AMG 510
(sotorasib), have demonstrated efficacy in KRAS G12C-mutant cancers, including non–small …
(sotorasib), have demonstrated efficacy in KRAS G12C-mutant cancers, including non–small …
Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK …
N Tanaka, JJ Lin, C Li, MB Ryan, J Zhang… - Cancer …, 2021 - europepmc.org
Abstract Mutant-selective KRAS G12C inhibitors, such as MRTX849 (adagrasib) and AMG
510 (sotorasib), have demonstrated efficacy in KRAS G12C-mutant cancers including non …
510 (sotorasib), have demonstrated efficacy in KRAS G12C-mutant cancers including non …
[PDF][PDF] Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK …
N Tanaka, JJ Lin, C Li, MB Ryan, J Zhang… - 2021 - academia.edu
Noritaka Tanaka1, Jessica J. Lin1, Chendi Li1, Meagan B. Ryan1, Junbing Zhang1, Lesli A.
Kiedrowski2, Alexa G. Michel1, Mohammed U. Syed1, Katerina A. Fella1, Mustafa Sakhi1 …
Kiedrowski2, Alexa G. Michel1, Mohammed U. Syed1, Katerina A. Fella1, Mustafa Sakhi1 …
[HTML][HTML] Clinical acquired resistance to KRASG12C inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK …
N Tanaka, JJ Lin, C Li, MB Ryan, J Zhang… - Cancer …, 2021 - ncbi.nlm.nih.gov
Abstract Mutant-selective KRAS G12C inhibitors, such as MRTX849 (adagrasib) and AMG
510 (sotorasib), have demonstrated efficacy in KRAS G12C-mutant cancers including non …
510 (sotorasib), have demonstrated efficacy in KRAS G12C-mutant cancers including non …
[PDF][PDF] Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK …
N Tanaka, JJ Lin, C Li, MB Ryan, J Zhang… - 2021 - biomed-phd.i-med.ac.at
Noritaka Tanaka1, Jessica J. Lin1, Chendi Li1, Meagan B. Ryan1, Junbing Zhang1, Lesli A.
Kiedrowski2, Alexa G. Michel1, Mohammed U. Syed1, Katerina A. Fella1, Mustafa Sakhi1 …
Kiedrowski2, Alexa G. Michel1, Mohammed U. Syed1, Katerina A. Fella1, Mustafa Sakhi1 …
Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK …
N Tanaka, JJ Lin, C Li, MB Ryan, J Zhang… - Cancer …, 2021 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title/>< jats: p> Mutant-selective
KRASG12C inhibitors, such as MRTX849 (adagrasib) and AMG 510 (sotorasib), have …
KRASG12C inhibitors, such as MRTX849 (adagrasib) and AMG 510 (sotorasib), have …
Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK …
N Tanaka, JJ Lin, C Li, MB Ryan, J Zhang… - Cancer …, 2021 - pubmed.ncbi.nlm.nih.gov
Mutant-selective KRAS G12C inhibitors, such as MRTX849 (adagrasib) and AMG 510
(sotorasib), have demonstrated efficacy in KRAS G12C-mutant cancers, including non-small …
(sotorasib), have demonstrated efficacy in KRAS G12C-mutant cancers, including non-small …